Clinical Trial Update: Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A phase 2 study evaluating the combination of RAD001 (everolimus) and bevacizumab in recurrent ovarian, fallopian tube, and primary peritoneal cancer has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Afinitor (everolimus)
• Avastin (bevacizumab)

Snippet

Sponsor: University of Pittsburgh | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-08-30